New Strategies in Combating Antibiotic Resistance: Insights from UMass Amherst and Microbiotix

by Santiago Fernandez
antibiotic-resistant superbugs

Groundbreaking research conducted by UMass Amherst and Microbiotix is addressing the critical issue of antibiotic-resistant superbugs. Their study introduces a new method focused on disrupting the Type 3 secretion system in pathogens, presenting an innovative way to combat infections. This approach is bolstered by cutting-edge luciferase-based technologies, opening avenues for new pharmaceutical developments and deepening our understanding of microbial infections, thereby marking a significant milestone in public health. Source:

Creation of a test to identify novel drugs that can neutralize pathogens, leading to substantial public health improvements.

The challenge of antibiotic-resistant superbugs, which undermine current medical treatments, is a pressing public health issue. The CDC reports that over 2.8 million such infections occur annually. Researchers globally are urgently seeking solutions to this problem.

Advancements in Understanding Pathogens

A team of researchers from the University of Massachusetts Amherst, in collaboration with Microbiotix scientists, have made a significant breakthrough, as published in the journal ACS Infectious Diseases. They have developed a method to target the Type 3 secretion system used by pathogens to infect host cells. The team has also created a test to identify new drugs that can attack this key cellular mechanism, thus making substantial advancements in public health.

Difficulties in Developing Antibiotics

Traditional methods of treating microbial infections involve using antibiotics that penetrate and destroy harmful cells. Designing an effective antibiotic is challenging as it must be both water-soluble for bloodstream transport and lipid-soluble to penetrate cellular membranes. Additionally, pathogenic cells have developed mechanisms like efflux pumps to expel antibiotics, further complicating drug design and effectiveness.

New Approaches to Tackle Superbugs

One approach is developing new antibiotics or combinations to outpace superbugs. Alternatively, as suggested by Alejandro Heuck, associate professor of biochemistry and molecular biology at UMass Amherst and the senior author of the paper, shifting focus from killing pathogens to disabling their mechanisms is viable. This strategy involves targeting the Type 3 secretion system, a unique feature of pathogenic microbes, reducing the pathogen’s effectiveness and allowing the host’s natural defenses to eliminate the infection.

Exploring Host-Pathogen Interactions

To invade host cells, pathogens use a syringe-like mechanism, the Type 3 secretion system, to inject proteins that facilitate infection. This system relies on the proteins PopD and PopB to form a tunnel through the host cell membrane. Disrupting this process can render the pathogen ineffective.

Revolutionary Research Methodology

Heuck’s team utilized luciferases, enzymes similar to those in lightning bugs, as tracers. They divided the enzyme and incorporated each half into the PopD/PopB proteins and host cells, respectively. Lighting up of host cells in the presence of certain chemical compounds indicates successful penetration by PopD/PopB, whereas darkness suggests a disruption of the translocon.

Impact and Funding of the Study

This research, while having clear implications in pharmaceuticals and public health, also enhances our understanding of microbial cell infection mechanisms. The study, titled “Cell-Based Assay to Determine Type 3 Secretion System Translocon Assembly in Pseudomonas aeruginosa Using Split Luciferase,” by Hanling Guo, Emily J. Geddes, Timothy J. Opperman, and Alejandro P. Heuck, was published on 18 November 2023 in ACS Infectious Diseases. It received support from the UMass Amherst Institute for Applied Life Sciences, the Healey Endowment Grant, and the National Institutes of Health.

Frequently Asked Questions (FAQs) about antibiotic-resistant superbugs

What is the focus of the recent research by UMass Amherst and Microbiotix?

The research conducted by UMass Amherst and Microbiotix focuses on addressing the issue of antibiotic-resistant superbugs. It introduces a novel approach that targets the Type 3 secretion system of pathogens to prevent infections. This method is supported by innovative luciferase-based technologies and aims to enhance the development of new drugs, contributing significantly to public health.

How does the Type 3 secretion system contribute to antibiotic resistance?

The Type 3 secretion system is a mechanism used by pathogens to infect host cells. It involves the creation of a tunnel through the host cell membrane using proteins like PopD and PopB. By targeting and disrupting this system, researchers aim to reduce the effectiveness of pathogens, thereby preventing them from developing resistance to antibiotics.

What challenges are faced in the development of new antibiotics?

Developing new antibiotics is challenging due to the need for the drug to be both water-soluble (for easy transport through the bloodstream) and lipid-soluble (to penetrate the cellular membrane of pathogens). Additionally, pathogenic cells have developed efflux pumps that can expel antibiotics, further complicating the development of effective treatments.

What alternative strategies are proposed against superbugs?

Aside from developing new antibiotics, an alternative strategy proposed by researchers involves shifting focus to disabling the mechanisms used by pathogens, such as the Type 3 secretion system. This approach aims to make pathogens ineffective without killing them, reducing the chance of them developing resistance.

What innovative research method was used in this study?

The research team used luciferases, enzymes similar to those in lightning bugs, as tracers. They incorporated halves of these enzymes into both the proteins used by pathogens (PopD/PopB) and host cells. This allowed them to identify chemical compounds that either facilitate or disrupt the formation of the translocon, a crucial step in pathogen infection.

More about antibiotic-resistant superbugs

  • UMass Amherst Research on Superbugs
  • Understanding the Type 3 Secretion System
  • Challenges in Antibiotic Development
  • New Approaches to Antibiotic Resistance
  • ACS Infectious Diseases Journal Article
  • National Institutes of Health Support for Research

You may also like


MikeD77 December 25, 2023 - 7:23 am

Interesting read but can someone explain more about luciferases? how do they exactly work in this context?

Emma_the_Reader December 25, 2023 - 9:01 am

does this mean we’re finally getting ahead of superbugs? been reading about them for ages and it’s always seemed so hopeless.

JohnSmith December 25, 2023 - 9:42 am

wow, this is really some groundbreaking stuff! The way they’re tackling the superbug crisis, just brilliant…

Sally_R December 25, 2023 - 6:35 pm

i’m not a scientist but this seems like a big deal? that type 3 secretion system sounds like key to stopping these bugs

CuriousCat December 25, 2023 - 7:58 pm

antibiotics resistance is scary stuff, glad to see smart people are on it… but how far are we from actual treatments?

ScienceFanatic December 26, 2023 - 1:04 am

I’ve been following antibiotic resistance for years, and this is one of the most promising developments I’ve seen. Hope it pans out.

HealthGuru101 December 26, 2023 - 3:53 am

Great to see UMass Amherst leading in this research, public health needs this kind of innovation. keep it up!


Leave a Comment

* By using this form you agree with the storage and handling of your data by this website.

SciTechPost is a web resource dedicated to providing up-to-date information on the fast-paced world of science and technology. Our mission is to make science and technology accessible to everyone through our platform, by bringing together experts, innovators, and academics to share their knowledge and experience.


Subscribe my Newsletter for new blog posts, tips & new photos. Let's stay updated!

© 2023 SciTechPost